Current Environment: Production

Suneet Agarwal | Education

Medical School

Harvard Medical School

2001, Boston, MA

Internship

Boston Children's Hospital

2002, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

2003, Boston, MA

Fellowship

Pediatric Hematology -Oncology

Dana Farber Cancer Institute/Children's Hospital Boston

2006, Boston, MA

Suneet Agarwal | Certifications

  • American Board of Pediatrics (Hematology-Oncology)

Suneet Agarwal | Media

Answers Blog

Becca Hudson has dyskeratosis congenita, causing her chromosomes’ telomeres to shorten and her tissues to age too soon. A new treatment that Dr. Suneet Agarwal hopes to test, thymidine, could build telomeres back up.

Suneet Agarwal | Publications

  1. ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders. J Clin Invest. 2025 Apr 15; 135(8). View ATM-dependent DNA damage response constrains cell growth and drives clonal hematopoiesis in telomere biology disorders. Abstract

  2. Metabolic constraint of human telomere length by nucleotide salvage efficiency. Nat Commun. 2025 Mar 27; 16(1):3000. View Metabolic constraint of human telomere length by nucleotide salvage efficiency. Abstract

  3. Chemotherapeutic 6-thio-2'-deoxyguanosine selectively targets and inhibits telomerase by inducing a non-productive telomere-bound telomerase complex. bioRxiv. 2025 Feb 19. View Chemotherapeutic 6-thio-2'-deoxyguanosine selectively targets and inhibits telomerase by inducing a non-productive telomere-bound telomerase complex. Abstract

  4. Identification of biallelic POLA2 variants in two families with an autosomal recessive telomere biology disorder. Eur J Hum Genet. 2025 May; 33(5):580-587. View Identification of biallelic POLA2 variants in two families with an autosomal recessive telomere biology disorder. Abstract

  5. Liver disease and transplantation in telomere biology disorders: An international multicenter cohort. Hepatol Commun. 2024 07 01; 8(7). View Liver disease and transplantation in telomere biology disorders: An international multicenter cohort. Abstract

  6. Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants? Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):135-140. View Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants? Abstract

  7. Successful cord blood transplantation for del7q myelodysplastic syndrome in Pearson marrow pancreas syndrome. Am J Hematol. 2023 12; 98(12):E376-E379. View Successful cord blood transplantation for del7q myelodysplastic syndrome in Pearson marrow pancreas syndrome. Abstract

  8. Publisher Correction: Thymidine nucleotide metabolism controls human telomere length. Nat Genet. 2023 Jul; 55(7):1251. View Publisher Correction: Thymidine nucleotide metabolism controls human telomere length. Abstract

  9. Single-cell multi-omics of mitochondrial DNA disorders reveals dynamics of purifying selection across human immune cells. Nat Genet. 2023 07; 55(7):1198-1209. View Single-cell multi-omics of mitochondrial DNA disorders reveals dynamics of purifying selection across human immune cells. Abstract

  10. Spectrum of Liver Pathology in Dyskeratosis Congenita. Am J Surg Pathol. 2023 08 01; 47(8):869-877. View Spectrum of Liver Pathology in Dyskeratosis Congenita. Abstract

  11. Thymidine nucleotide metabolism controls human telomere length. Nat Genet. 2023 04; 55(4):568-580. View Thymidine nucleotide metabolism controls human telomere length. Abstract

  12. Domain specific mutations in dyskerin disrupt 3' end processing of scaRNA13. Nucleic Acids Res. 2022 09 09; 50(16):9413-9425. View Domain specific mutations in dyskerin disrupt 3' end processing of scaRNA13. Abstract

  13. Congenital X-linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6. Am J Hematol. 2022 01 01; 97(1):18-29. View Congenital X-linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6. Abstract

  14. The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 09 09; 138(10):898-911. View The clinical and functional effects of TERT variants in myelodysplastic syndrome. Abstract

  15. Hepatic vascular remodelling in a patient with dyskeratosis congenita. Histopathology. 2022 01; 80(2):450-453. View Hepatic vascular remodelling in a patient with dyskeratosis congenita. Abstract

  16. Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. Proc Natl Acad Sci U S A. 2021 08 10; 118(32). View Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. Abstract

  17. Mitochondrial function in development and disease. Dis Model Mech. 2021 06 01; 14(6). View Mitochondrial function in development and disease. Abstract

  18. Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020 12 24; 136(26):3070-3081. View Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Abstract

  19. Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. J Pediatr. 2021 03; 230:55-61.e4. View Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. Abstract

  20. Telomerase RNA processing: Implications for human health and disease. Stem Cells. 2020 Sep 01. View Telomerase RNA processing: Implications for human health and disease. Abstract

  21. Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. Blood. 2020 Aug 17. View Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. Abstract

  22. Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. ERJ Open Res. 2020 Apr; 6(2). View Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. Abstract

  23. Impaired reproductive function and fertility preservation in a woman with a dyskeratosis congenita. J Assist Reprod Genet. 2020 May; 37(5):1221-1225. View Impaired reproductive function and fertility preservation in a woman with a dyskeratosis congenita. Abstract

  24. Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell. 2020 06 04; 26(6):896-909.e8. View Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Abstract

  25. Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis. 2019 02; 22(1):95-102. View Understanding the evolving phenotype of vascular complications in telomere biology disorders. Abstract

  26. Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita. Hematol Oncol Clin North Am. 2018 Aug; 32(4):669-685. View Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita. Abstract

  27. Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR-Cas9 genome editing. Nat Biomed Eng. 2017 11; 1(11):878-888. View Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR-Cas9 genome editing. Abstract

  28. Exudative Vitreoretinopathy in Dyskeratosis Congenita. Ophthalmology. 2017 08; 124(8):1246. View Exudative Vitreoretinopathy in Dyskeratosis Congenita. Abstract

  29. Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Sci Transl Med. 2017 02 08; 9(376). View Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Abstract

  30. Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. Eur Respir J. 2017 01; 49(1). View Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. Abstract

  31. Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies. Ophthalmic Genet. 2017 Jan-Feb; 38(1):51-60. View Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies. Abstract

  32. Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. PLoS One. 2016; 11(9):e0162409. View Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. Abstract

  33. A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. Blood. 2016 10 20; 128(16):2089-2092. View A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. Abstract

  34. Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. J Clin Invest. 2016 09 01; 126(9):3377-82. View Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. Abstract

  35. Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component. Nat Genet. 2015 Dec; 47(12):1482-8. View Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component. Abstract

  36. Simultaneous sequencing of oxidized methylcytosines produced by TET/JBP dioxygenases in Coprinopsis cinerea. Proc Natl Acad Sci U S A. 2014 Dec 02; 111(48):E5149-58. View Simultaneous sequencing of oxidized methylcytosines produced by TET/JBP dioxygenases in Coprinopsis cinerea. Abstract

  37. Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia. Blood. 2014 Jul 17; 124(3):437-40. View Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia. Abstract

  38. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013 Jul; 31(7):1287-97. View Induced pluripotent stem cells with a mitochondrial DNA deletion. Abstract

  39. A young adult with aplastic anemia and gray hair. Clin Chem. 2013 Jan; 59(1):47-50. View A young adult with aplastic anemia and gray hair. Abstract

  40. The GLIB technique for genome-wide mapping of 5-hydroxymethylcytosine. Nat Protoc. 2012 Oct; 7(10):1909-17. View The GLIB technique for genome-wide mapping of 5-hydroxymethylcytosine. Abstract

  41. CTC1 Mutations in a patient with dyskeratosis congenita. Pediatr Blood Cancer. 2012 Aug; 59(2):311-4. View CTC1 Mutations in a patient with dyskeratosis congenita. Abstract

  42. Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Cell Res. 2011 Aug; 21(8):1157-60. View Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Abstract

  43. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011 May 19; 473(7347):394-7. View Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Abstract

  44. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011 Mar 03; 471(7336):63-7. View Somatic coding mutations in human induced pluripotent stem cells. Abstract

  45. Cellular therapy for fanconi anemia: the past, present, and future. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S109-14. View Cellular therapy for fanconi anemia: the past, present, and future. Abstract

  46. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol. 2011 Jun; 127(6):1400-7.e4. View Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. Abstract

  47. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010 Dec 09; 468(7325):839-43. View Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Abstract

  48. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010 Dec; 42(12):1113-7. View Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Abstract

  49. Dynamic instability of genomic methylation patterns in pluripotent stem cells. Epigenetics Chromatin. 2010 Sep 24; 3(1):17. View Dynamic instability of genomic methylation patterns in pluripotent stem cells. Abstract

  50. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010 Jul 02; 7(1):15-9. View Reprogramming of T cells from human peripheral blood. Abstract

  51. AID for reprogramming. Cell Res. 2010 Mar; 20(3):253-5. View AID for reprogramming. Abstract

  52. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature. 2010 Mar 11; 464(7286):292-6. View Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Abstract

  53. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010 Feb; 54(2):273-8. View Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Abstract

  54. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009 May 15; 324(5929):930-5. View Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Abstract

  55. Generation of induced pluripotent stem cells from human blood. Blood. 2009 May 28; 113(22):5476-9. View Generation of induced pluripotent stem cells from human blood. Abstract

  56. Current prospects for the generation of patient-specific pluripotent cells from adult tissues. Regen Med. 2007 Sep; 2(5):743-52. View Current prospects for the generation of patient-specific pluripotent cells from adult tissues. Abstract

  57. Cardiac troponin increases among runners in the Boston Marathon. Ann Emerg Med. 2007 Feb; 49(2):137-43, 143.e1. View Cardiac troponin increases among runners in the Boston Marathon. Abstract

  58. Deletion of a conserved Il4 silencer impairs T helper type 1-mediated immunity. Nat Immunol. 2004 Dec; 5(12):1251-9. View Deletion of a conserved Il4 silencer impairs T helper type 1-mediated immunity. Abstract

  59. TID1, a mammalian homologue of the drosophila tumor suppressor lethal(2) tumorous imaginal discs, regulates activation-induced cell death in Th2 cells. Oncogene. 2003 Jul 24; 22(30):4636-41. View TID1, a mammalian homologue of the drosophila tumor suppressor lethal(2) tumorous imaginal discs, regulates activation-induced cell death in Th2 cells. Abstract

  60. A 3' enhancer in the IL-4 gene regulates cytokine production by Th2 cells and mast cells. Immunity. 2002 Jul; 17(1):41-50. View A 3' enhancer in the IL-4 gene regulates cytokine production by Th2 cells and mast cells. Abstract

  61. Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Immunity. 2002 May; 16(5):649-60. View Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene. Abstract

  62. Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo. Immunity. 2000 Jun; 12(6):643-52. View Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo. Abstract

  63. Chromatin-based regulatory mechanisms governing cytokine gene transcription. J Allergy Clin Immunol. 1999 Jun; 103(6):990-9. View Chromatin-based regulatory mechanisms governing cytokine gene transcription. Abstract

  64. Regulation of cytokine gene expression during T cell differentiation. 1999.

  65. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity. 1998 Dec; 9(6):765-75. View Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Abstract

  66. Long-range transcriptional regulation of cytokine gene expression. Curr Opin Immunol. 1998 Jun; 10(3):345-52. View Long-range transcriptional regulation of cytokine gene expression. Abstract

  67. Genetic-based strategies for control of HIV-1: Tat and Rev as targets. . Drug News and Perspectives. 1996; 9(4):220-227.

BESbswy